Annual Accounts Payable
$3.54 M
+$982.00 K+38.34%
December 31, 2023
Summary
- As of March 5, 2025, CYCC annual accounts payable is $3.54 million, with the most recent change of +$982.00 thousand (+38.34%) on December 31, 2023.
- During the last 3 years, CYCC annual accounts payable has risen by +$3.03 million (+589.30%).
- CYCC annual accounts payable is now -28.54% below its all-time high of $4.96 million, reached on December 31, 2007.
Performance
CYCC Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$4.13 M
-$615.00 K-12.97%
September 30, 2024
Summary
- As of March 5, 2025, CYCC quarterly accounts payable is $4.13 million, with the most recent change of -$615.00 thousand (-12.97%) on September 30, 2024.
- Over the past year, CYCC quarterly accounts payable has increased by +$583.00 thousand (+16.45%).
- CYCC quarterly accounts payable is now -20.65% below its all-time high of $5.20 million, reached on March 31, 2024.
Performance
CYCC Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
CYCC Accounts Payable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +38.3% | +16.4% |
3 y3 years | +589.3% | +64.5% |
5 y5 years | +30.3% | +64.5% |
CYCC Accounts Payable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +67.4% | -20.6% | +319.7% |
5 y | 5-year | at high | +589.3% | -20.6% | +1550.4% |
alltime | all time | -28.5% | +589.3% | -20.6% | +1550.4% |
Cyclacel Pharmaceuticals Accounts Payable History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $4.13 M(-13.0%) |
Jun 2024 | - | $4.74 M(-8.8%) |
Mar 2024 | - | $5.20 M(+46.8%) |
Dec 2023 | $3.54 M(+38.3%) | $3.54 M(+125.5%) |
Sep 2023 | - | $1.57 M(-27.6%) |
Jun 2023 | - | $2.17 M(-13.6%) |
Mar 2023 | - | $2.51 M(-2.0%) |
Dec 2022 | $2.56 M(+21.0%) | $2.56 M(+160.5%) |
Sep 2022 | - | $983.00 K(-55.4%) |
Jun 2022 | - | $2.21 M(-22.6%) |
Mar 2022 | - | $2.85 M(+34.6%) |
Dec 2021 | $2.12 M(+311.9%) | $2.12 M(+39.7%) |
Sep 2021 | - | $1.51 M(+26.6%) |
Jun 2021 | - | $1.20 M(+37.4%) |
Mar 2021 | - | $871.00 K(+69.5%) |
Dec 2020 | $514.00 K(-42.2%) | $514.00 K(+13.0%) |
Sep 2020 | - | $455.00 K(+33.0%) |
Jun 2020 | - | $342.00 K(+36.8%) |
Mar 2020 | - | $250.00 K(-71.9%) |
Dec 2019 | $890.00 K(-67.3%) | $890.00 K(+0.3%) |
Sep 2019 | - | $887.00 K(-19.8%) |
Jun 2019 | - | $1.11 M(-13.9%) |
Mar 2019 | - | $1.28 M(-52.8%) |
Dec 2018 | $2.72 M(+74.5%) | $2.72 M(+92.7%) |
Sep 2018 | - | $1.41 M(-15.8%) |
Jun 2018 | - | $1.68 M(-14.1%) |
Mar 2018 | - | $1.95 M(+25.1%) |
Dec 2017 | $1.56 M(-37.6%) | $1.56 M(-21.0%) |
Sep 2017 | - | $1.97 M(-3.2%) |
Jun 2017 | - | $2.04 M(+23.4%) |
Mar 2017 | - | $1.65 M(-33.8%) |
Dec 2016 | $2.50 M(+28.7%) | $2.50 M(+26.2%) |
Sep 2016 | - | $1.98 M(+4.3%) |
Jun 2016 | - | $1.90 M(+20.0%) |
Mar 2016 | - | $1.58 M(-18.5%) |
Dec 2015 | $1.94 M(-30.5%) | $1.94 M(+20.0%) |
Sep 2015 | - | $1.62 M(-38.1%) |
Jun 2015 | - | $2.61 M(-34.9%) |
Mar 2015 | - | $4.01 M(+43.5%) |
Dec 2014 | $2.79 M | $2.79 M(+26.9%) |
Sep 2014 | - | $2.20 M(-51.6%) |
Jun 2014 | - | $4.54 M(-3.7%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2014 | - | $4.72 M(+85.4%) |
Dec 2013 | $2.54 M(+12.7%) | $2.54 M(+8.2%) |
Sep 2013 | - | $2.35 M(-3.5%) |
Jun 2013 | - | $2.44 M(-13.7%) |
Mar 2013 | - | $2.83 M(+25.1%) |
Dec 2012 | $2.26 M(+31.6%) | $2.26 M(+37.6%) |
Sep 2012 | - | $1.64 M(+6.3%) |
Jun 2012 | - | $1.54 M(+38.4%) |
Mar 2012 | - | $1.12 M(-35.0%) |
Dec 2011 | $1.72 M(-0.3%) | $1.72 M(+55.9%) |
Sep 2011 | - | $1.10 M(-0.3%) |
Jun 2011 | - | $1.10 M(+16.6%) |
Mar 2011 | - | $947.00 K(-45.0%) |
Dec 2010 | $1.72 M(+0.8%) | $1.72 M(+28.6%) |
Sep 2010 | - | $1.34 M(-13.5%) |
Jun 2010 | - | $1.55 M(-13.0%) |
Mar 2010 | - | $1.78 M(+4.3%) |
Dec 2009 | $1.71 M(+126.7%) | $1.71 M(+16.8%) |
Sep 2009 | - | $1.46 M(+1.6%) |
Jun 2009 | - | $1.44 M(-20.5%) |
Mar 2009 | - | $1.81 M(+140.3%) |
Dec 2008 | $754.00 K(-84.8%) | $754.00 K(-42.0%) |
Sep 2008 | - | $1.30 M(-38.9%) |
Jun 2008 | - | $2.13 M(-38.1%) |
Mar 2008 | - | $3.44 M(-30.6%) |
Dec 2007 | $4.96 M(+128.0%) | $4.96 M(+147.4%) |
Sep 2007 | - | $2.00 M(+1.0%) |
Jun 2007 | - | $1.99 M(-4.4%) |
Mar 2007 | - | $2.08 M(-4.6%) |
Dec 2006 | $2.17 M(+0.7%) | $2.17 M(+44.5%) |
Sep 2006 | - | $1.50 M(-21.1%) |
Jun 2006 | - | $1.91 M(-39.5%) |
Mar 2006 | - | $3.15 M(+46.0%) |
Dec 2005 | $2.16 M(+26.5%) | $2.16 M(+144.8%) |
Sep 2005 | - | $882.00 K(+39.3%) |
Jun 2005 | - | $633.00 K(-47.5%) |
Mar 2005 | - | $1.21 M(-29.4%) |
Dec 2004 | $1.71 M(+78.9%) | $1.71 M(-21.0%) |
Sep 2004 | - | $2.16 M(+5.7%) |
Jun 2004 | - | $2.04 M(+197.2%) |
Mar 2004 | - | $688.00 K(-27.9%) |
Dec 2003 | $954.00 K | $954.00 K |
FAQ
- What is Cyclacel Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals annual accounts payable year-on-year change?
- What is Cyclacel Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals quarterly accounts payable year-on-year change?
What is Cyclacel Pharmaceuticals annual accounts payable?
The current annual accounts payable of CYCC is $3.54 M
What is the all time high annual accounts payable for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high annual accounts payable is $4.96 M
What is Cyclacel Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, CYCC annual accounts payable has changed by +$982.00 K (+38.34%)
What is Cyclacel Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of CYCC is $4.13 M
What is the all time high quarterly accounts payable for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high quarterly accounts payable is $5.20 M
What is Cyclacel Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, CYCC quarterly accounts payable has changed by +$583.00 K (+16.45%)